Bristol-myers Squibb Compnay

Medarex Inc.

E. R. Squibb Sons, Inc.

Ono Pharmaceutical Co., Ltd.

Network Appliance, Inc.

Schering Corporation

Netapp, Inc.

Ibio Limited

Merck Sharp + Dohme Corp.

Synthon B.v.

Mohan Srinivasan

Alan J Korman

Haichun Huang

Mark J Selby

Changyu Wang

Josephine M Cardarelli

Guodong Chen

Nils Lonberg

Indrani Chakraborty

Richard Y Huang

Karla Ann Henning

David B Passmore

Michelle Minhua Han

Alison Witte

Vijayan Rajan

Paul O Sheppard

Aaron Paul Yamniuk

Mark F Maurer

Haibin Chen

Shrikant Deshpande

Leonard G Presta

Arthur F Lent

Peter Brams

Xi-Tao Wang

Denise Leah Williams

Jonathan A Pachter

Jeffrey S Kimmel

Maria N Jure-Kunkel

Stanley Richard Krystek, Jr

Scott R Presnell

Arvind Rajpal

Mark W Rixon

Brigitte Devaux

Kent B Thudium

Han Chang

Brenda L Stevens

Tibor P Keler

Ginger Chao Rakestraw

Israel Lowy

Edward L Halk

Joseph C Pittman

Laura A Vitale

Blake H Lewis

Gregory D Vite

Yong Zhang

Pavel Strop

Robert F Graziano

Paul E Morin

David Brittain Bolen

Sarah Lee Pogue

Amelia Nancy Black

Huiming Li

Susan Wong

Bingliang Chen

Herman Lee

Bryan C Barnhart

Brian J Pawlowski

Thomas D Kempe

Ming Lei

Liang Schweizer

Sandra V Hatcher

Susan Chien-Szu Wong

Yan Wang

Robert Greenberg

Diane Feingersh

Judith Hailey

Martin J Corbett

John S Sack

Emanuela Sega

Pingping Zhang

Jochem Gokemeijer

Alexander T Kozhich

Lynn F Dickey

Angela Goodenough

Joseph E Myers, Jr

Daniel F Ardourel

Hans S Keirstead

Vangipuram S Rangan

Hui Wei

Tseng-hui Timothy Chen

Michael Quigley

Xiang Shao

Lumelle A Schneeweis

Hadia Lemar

Susan H Julien

Yinfung Fong

Matthew Paul Greving

Steven Sheriff

John P Throup

Ekaterina G Deyanova

Chetana Rao-Naik

Bing Li

Michelle Renee Kuhne

Li-Sheng Lu

Angeles Estelles

Charles G Peele

Jun Zhang

Natalie Bezman

Alla Pritsker

Virginie Lafont

Provided herein engineered polypeptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a CD25 reference target, and methods of selecting said engineered polypeptides. Further provided are methods of using the engineered polypeptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules such as antibodies. Further provided herein are CD25 antibodies selected using these engineered polypeptides.

Engineered CD25 polypeptides and uses thereof

Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.

CD25 antibodies

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Antibodies to TIGIT

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

IP-10 antibodies and their uses

A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Prodruggable antibodies, prodrugs thereof, and methods of use and making

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against OX-40 and uses thereof

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Anti-GITR antibodies for cancer diagnostics

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Antibodies against MICA and/or MICB and uses thereof

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.

Interferon receptor 1 antibodies and their uses

Growing community of inventors

Cupertino, CA, United States of America

Mohan Srinivasan